Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Second new facility built by Fluor on Bayerโ€™s Biotech campus in Berkeley

Fluor Corporation (NYSE: FLR) announced today that it has completed construction of Bayerโ€™s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees and clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231018153130/en/

Bayer's first global Cell Therapy Launch Facility was recently completed by Fluor Corporation. The new, state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs. (Photo: Business Wire)

Bayer's first global Cell Therapy Launch Facility was recently completed by Fluor Corporation. The new, state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs. (Photo: Business Wire)

โ€œFluorโ€™s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,โ€ said Richard Meserole, president of Fluorโ€™s Advanced Technologies & Life Sciences business line. โ€œThe project was phased to allow start-up activities to commence as needed to support production timeline.โ€

The new state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.

Fluorโ€™s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Fluor also completed construction of Bayerโ€™s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayerโ€™s teams producing multiple biologic therapies.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clientsโ€™ greatest challenges. Fluorโ€™s 40,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $13.7 billion in 2022 and is ranked 303 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#ATLS

Fluor completes Bayerโ€™s first global Cell Therapy Launch Facility in Berkeley, California

Contacts

Brett Turner

Media Relations

864.281.6976

Jason Landkamer

Investor Relations

469.398.7222

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.08
-0.28 (-0.11%)
AAPL  273.43
+0.26 (0.10%)
AMD  305.33
+1.87 (0.62%)
BAC  52.47
-0.65 (-1.22%)
GOOG  337.75
+0.02 (0.01%)
META  659.15
-15.57 (-2.31%)
MSFT  415.75
-17.17 (-3.97%)
NVDA  199.64
-2.86 (-1.41%)
ORCL  176.28
-11.22 (-5.98%)
TSLA  373.72
-13.79 (-3.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gift this article